- Home
- ALNY vs CSX Comparison
ALNY vs CSX Comparison
Compare ALNY & CSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALNY
- CSX
- Stock Information
- Founded
- ALNY 2002
- CSX 1978
- Country
- ALNY United States
- CSX United States
- Employees
- ALNY N/A
- CSX N/A
- Industry
- ALNY Biotechnology: Pharmaceutical Preparations
- CSX Railroads
- Sector
- ALNY Health Care
- CSX Industrials
- Exchange
- ALNY Nasdaq
- CSX Nasdaq
- Market Cap
- ALNY 60.7B
- CSX 67.4B
- IPO Year
- ALNY 2004
- CSX N/A
- Fundamental
- Price
- ALNY $449.56
- CSX $35.64
- Analyst Decision
- ALNY Strong Buy
- CSX Buy
- Analyst Count
- ALNY 27
- CSX 22
- Target Price
- ALNY $472.81
- CSX $38.41
- AVG Volume (30 Days)
- ALNY 1.1M
- CSX 13.6M
- Earning Date
- ALNY 10-30-2025
- CSX 10-16-2025
- Dividend Yield
- ALNY N/A
- CSX 1.47%
- EPS Growth
- ALNY N/A
- CSX N/A
- EPS
- ALNY 0.33
- CSX 1.54
- Revenue
- ALNY $3,210,070,000.00
- CSX $14,123,000,000.00
- Revenue This Year
- ALNY $60.04
- CSX N/A
- Revenue Next Year
- ALNY $40.69
- CSX $4.17
- P/E Ratio
- ALNY $1,362.90
- CSX $23.15
- Revenue Growth
- ALNY 53.24
- CSX N/A
- 52 Week Low
- ALNY $205.87
- CSX $26.22
- 52 Week High
- ALNY $495.55
- CSX $37.25
- Technical
- Relative Strength Index (RSI)
- ALNY 42.97
- CSX 51.81
- Support Level
- ALNY $456.90
- CSX $35.06
- Resistance Level
- ALNY $485.36
- CSX $36.34
- Average True Range (ATR)
- ALNY 18.16
- CSX 0.65
- MACD
- ALNY -2.11
- CSX -0.16
- Stochastic Oscillator
- ALNY 22.10
- CSX 27.46
About ALNY Alnylam Pharmaceuticals Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
About CSX CSX Corporation
Operating in the Eastern United States, Class I railroad CSX generated revenue near $14.5 billion in 2024. On its more than 21,000 miles of track, CSX hauls shipments of coal (16% of consolidated revenue), chemicals (17%), intermodal containers (16%), automotive cargo (7%), and a diverse mix of other bulk and industrial merchandise.